Voorwaarde voor herstel is echt: Pinto schop onder de kont. Met die Pinto wordt het niets. Hier een klein stukje van al zijn niet uitgekomen praatjes.
"Leiden, The Netherlands, July 21, 2006
'The MAA submission is a significant milestone in the development of rhC1INH and demonstrates our commitment to provide a highly effective therapy for patients living with the burden of hereditary angioedema,' said Dr. Francis Pinto, CEO of Pharming. 'For Pharming, the rhC1INH submission represents a major leap forward in its evolution as a product-focused biotech company addressing unmet medical needs.'
Leiden, The Netherlands, August 4, 2006
“Pharming has achieved significant milestones with the submission of the MAA for rhC1INH with the EMEA, the Fast Track designation on rhC1INH for HAE and Orphan Drug designations on rhC1INH for new indications from the FDA,' said Dr. Francis J. Pinto, CEO of Pharming. 'In the first half of 2006, Pharming attained a solid cash position through key transactions and well controlled costs and expenses.'
Leiden, The Netherlands, October 27, 2006.
“In the first nine months of 2006, Pharming strengthened its cash position through key transactions and well controlled costs and expenses,” said Dr. Francis J. Pinto, CEO of Pharming. “With the filing of the Marketing Authorization Application for Rhucin® in Europe, the finalization of the acquisition of DNage and our move to the new Beagle research headquarters, Pharming has completed a remarkable transformation of its product pipeline and research platforms. With the focus on bringing Rhucin® to market as quickly as possible and prospects for licensing agreements and research collaborations, Pharming is positioned for strong growth in the near future.”
Leiden, The Netherlands, February 16, 2007
“In 2006, Pharming strengthened its cash position, filed its Marketing Authorization Application for Rhucin® in Europe, developed new research initiatives, acquired DNage and moved to the new Beagle research headquarters,” said Dr. Francis J. Pinto, CEO of Pharming. “With these and other developments, the Company is well positioned to deliver on its ambition to become a leading player in the biopharmaceutical sector with highly profitable products on the market and a strong pipeline of innovative products based on excellent research.”
Leiden, The Netherlands, April 20, 2007.
“In the first quarter of 2007, Pharming continued its preparations for market authorization of Rhucin® in Europe and strengthened its focus on commercial development,” said Dr. Francis J. Pinto, CEO of Pharming. “We are working hard towards succesfull completion of the regulatory review process for our first products later this year. We are confident that our efforts will also form the basis for strengthening our product portfolio and expanding our research engine.”
Leiden, The Netherlands, July 20, 2007
Dr. Francis J. Pinto, Chief Executive Officer of Pharming, commented: “During the first six months of this year we made significant progress in the development of our lead product Rhucin®.
Leiden, The Netherlands, October 19, 2007.
Dr. Francis J. Pinto, Chief Executive Officer of Pharming, commented: “In the third quarter of this year we have been highly focused on getting our lead product Rhucin® to market as soon as possible, while maintaining a low cash-burn rate.
December 13, 2007 ·
Pharming Prepares To Appeal Ruling On European Marketing Authorization Application For Rhucin® ...
Tja na 5 jaar jaar van geweldige progress, accelaration and continue blijschap bij de heer Pinto is het resultaat bekend: afgekeurd."
Dit is van Steven onder zijn mirrordraadje en dan nog maar een deel ervan. Steven heeft het zeer goed allemaal op een rij gezet. Als ik hem 10 AB's kon geven, dan had hij die gekregen.
Het Pharmingdal is dus wel duidelijk. Dat weten de Pharmingbeleggers maar al te goed inmiddels. De vraag is: hoe kan het beter? Daarover heb ik wat aanzetten gegeven, maar veel reacties krijg ik niet. Is er gebrek aan creativiteit? Is er eenzijdige gerichtheid op omhoog praten? Merkwaardig, heel merkwaardig!
Groet, Jonas